200 ϫ 10 compared with the remaining 285 patients with CVID. The patients with LOCID more frequently belonged to consanguineous families (29% vs 8%; ). They differed from patients with CVID with a higher prevalence P p .004 of splenomegaly (64% vs 31%), granuloma (43% vs 10%), gastrointestinal disease (75% vs 42%), and lymphoma (29% vs 4%). Even on immunoglobulin substitution, they required more frequent antibiotics administration and hospitalization. Lymphocyte counts were lower, with a marked decrease in CD4 + T cell counts ( vs 6 158 ϫ 10 cells/L;
) and a severe defect in naive CD45RA + CCR7 + CD4 + T cell counts (!20% of total CD4 + 6 604 ϫ 10 P ! .001 T cells in 71% of patients with LOCID vs 37% of patients with CVID;
). The CD19 + B cell compartment P p .001 was also significantly decreased ( vs cells/L; ). 6 6 20 ϫ 10 102 ϫ 10 P ! .001 Conclusions. LOCID differs from classic CVID in its clinical and immunologic characteristics. Systematic T cell phenotype may help to discriminate such patients from those with CVID. Identification of this phenotype should result in a more fitted diagnostic and therapeutic approach of infections and could provide insights for genetic diagnosis.
Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by defective antibody production and hypogammaglobulinemia [1] .
CVID likely encompasses a heterogeneous group of diseases with common clinical features, including recurrent infections of the respiratory tract and less frequently autoimmune, granulomatous, or lymphoproliferative disorders. In fact, CVID is a descriptive term originally used by a World Health Organization committee to include patients with a range of immunoglobulin deficiencies that remained unclassified [2] . Despite the major advances achieved in the molecular and cellular characterization of primary immunodeficiencies [3, 4] , CVID still represents the most common form of clinically significant antibody failure. A small number of genetic abnormalities involving different immune pathways have been demonstrated in !10% of patients with CVID to date [5] [6] [7] . However, the great heterogeneity of CVID has hindered progress in the pathogenic understanding of most patients with CVID. Recent classifications, based on biological [8, 9] and clinical features [10] , may provide the basis for further correlations with genetic markers.
The existence of T cell dysfunction in CVID and its possible implication in disease pathogenesis and clinical course have been emphasized for many years [11] . In a large survey of patients with CVID [12] , defective in vitro T cell function has been reported and associated with a higher risk of death. More recently, Giovanetti et al [9] demonstrated that the severity of the multiple T cell abnormalities observed in their patients with CVID was reflected in a parallel loss of CD4 + naive T cells and showed a strong negative correlation for naive CD4 + T cell values and overall clinical severity of the disease. Severe T cell deficiency, as evidenced by the occurrence of opportunistic infections (OIs), has been occasionally described in series of patients with CVID [12] [13] [14] or in case reports [15] [16] [17] . A previous large European study did not consider OIs because the focus was on disease progression rather than infective complications [10] .
Within the French DEFI series of patients with primary hypogammaglobulinemia [18] , we have specifically studied patients with CVID who had experienced OIs and/or had a CD4 T cell count ! cells/L. The aims of our study were to 6 200 ϫ 10 determine the characteristics of this subset of patients with both hypogammaglobulinemia and severe T cell deficiency and to define a distinct group of patients with late-onset combined immune deficiency (LOCID).
METHODS
Patients. DEFI is a French national study on adults with primary hypogammaglobulinemia [18] . The study has been approved by the local ethics committee and all patients gave written informed consent, including consent for potential genetic studies. A total of 313 patients with CVID from 41 centers were enrolled in this cohort from April 2004 through April 2008. The diagnostic criteria used were consistent with the European Society for Immunodeficiencies/Pan-American Group for Immunodeficiency criteria: age older than 4 years, serum immunoglobulin G (IgG) level below the lower reference range, and exclusion of an underlying cause [19] . For each patient, infectious, autoimmune, lymphoproliferative, or tumoral complications were compiled in a clinical file along with family medical history. The median age at evaluation was 45 years.
Patients were considered to have severe T cell deficiency (LOCID group) if they were recorded as having a previous infection indicative of a severe defect in cell-mediated immunity and/or had a CD4 + T lymphocyte count ! cells/L at 6 200 ϫ 10 the time of evaluation. Infections indicative of severe T cell defect were consistent with the revised classification system of the manifestations of human immunodeficiency virus (HIV) infection and were referred to as OIs [20] . Unusual infections, such as pulmonary tuberculosis (4 patients) or recurrent herpes infections, were not considered in the present study because they may also occur in patients without severe immune deficiency. Patients who did not belong to the LOCID group were referred to as the CVID group for comparison analysis. Immunologic evaluation, genetic screening, and HIV testing. A blood sample collected on the day of enrollment was used to determine detailed B and T cell phenotypes. Systematic sequencing of the genes coding for the CD40 ligand, the Signaling lymphocyte activation molecule-Associated Protein, and Bruton tyrosine kinase was performed for all male patients of the DEFI study to exclude patients with X-linked hyperIgM, X-linked lymphoproliferative disease, or X-linked agammaglobulinemia from the CVID group. HIV viral load was quantified on frozen plasma using an HIV viral load test (Roche Diagnostics).
Statistical analysis. Data collection was validated through double data capture. Statistical comparisons between characteristics of patients (with and without OIs) were based on the nonparametric Wilcoxon rank-sum test for continuous variables and the Pearson x 2 test or the Fisher exact test for frequencies. All reported P values are 2-tailed. Statistical analyses were performed using Stata, version 9.2 (Stata). 200 ϫ 10 previous OIs. Altogether, 28 patients (8.9%) were considered to have a major cellular immune defect combined with hypogammaglobulinemia (LOCID group). Main clinical characteristics of these patients are provided in Table 2 . Median age at occurrence of the first OI was 33 years. The sex ratio was comparable in both groups. We found a higher prevalence of consanguineous families in the LOCID group compared with the CVID group (29% vs 8%;
RESULTS

Clinical
). Family cases were as P p .004 frequent in patients LOCID and patients with CVID (18% and 22%, respectively;
). The first symptoms indicative of P p .54 hypogammaglobulinemia were reported at a median age of 19 years in both groups, and diagnosis of hypogammaglobulinemia was made at 31 years for the LOCID patients versus 35 years for the patients with CVID ( ). P p .20 At the time of immunologic evaluation, the median age was 43 years for patients with LOCID and 46 years for patients with CVID. Median time from first symptoms to evaluation was comparable in the LOCID and CVID groups (17 and 18 years, respectively; . Median time from first symptoms P p .80 indicative of humoral deficiency to OI occurrence was 17 years (interquartile range, 6-26 years). Median time from OI occurrence to evaluation was 3 years 3 months (interquartile range, 1-10 months). Steroids intake at the time of evaluation was not significantly higher in the LOCID group (18% in the LOCID group and 12% in the CVID group;
). Details P p .15 on immunosuppressive therapy (dose and drug) are indicated in Tables 1 and 3 . One of 17 patients with previous OIs had been taking low-dose prednisone (0.12 mg/kg daily) for autoimmune hemolytic anemia before developing pneumocystosis. Another patient had been treated with alemtuzumab before she developed an adenovirus infection. Of note, this patient had previously developed systemic toxoplasmosis before any immunosuppressive therapy. The patients with LOCID received immunoglobulin substitution as frequently as the patients with CVID (82% and 77%, respectively). Clinical severity of the disease was evaluated at inclusion in patients receiving immunoglobulin substitution on the basis of the requirement and duration of antibiotic administration within the last 12 months before registration. Antibiotics administration for a cumulative period of 8 weeks or more was more frequently observed among patients with LOCID than among patients with CVID (47% vs 21%;
). Need for hospitalization during the last 12 P p .02 months was also more frequent among patients with LOCID (57% vs 26%;
). Interestingly, in the patients receiving P p .003 immunoglobulin substitution, bronchiectasis was more frequently observed among the patients with LOCID than among the patients with CVID (61% vs 37%;
). Pneumonia P p .021 was also reported more frequently in the LOCID group, albeit not significantly (68% vs 56%;
). P p .23 Some clinical features were strongly associated with severe T cell defect (Table 2) . Splenomegaly was more frequently observed among the patients with LOCID (64% vs 31%; P ! ). Granulomatous disease was demonstrated in 43% of pa-.001 tients with LOCID versus only 11% of patients with CVID ( ). Gastrointestinal disease was also more frequent P ! .001 among the patients with LOCID (75% vs 42%;
). Con-P p .001 versely, autoimmune cytopenia was as frequent in both groups (18%). Solid organ-specific autoimmunity was also reported equally in both groups (14% and 18%, respectively;
). P p .414 The risk of developing lymphoma appeared increased because 5 patients with LOCID (29%) developed lymphoma versus 13 (4%) of 285 patients with CVID ( ). Three of these 5 P p .001 lymphomas were associated with Epstein-Barr virus (EBV): 2 EBV-positive B cell non-Hodgkin lymphomas and 1 EBV-positive Hodgkin lymphoma. The non-EBV-related lymphomas were a B cell and a T cell non-Hodgkin lymphoma. Four of the 5 lymphomas were diagnosed more than 2 years after first symptoms indicative of hypogammaglobulinemia. The EBVpositive Hodgkin lymphoma was diagnosed concomitantly to a marked hypogammaglobulinemia (undetectable IgA and IgM; IgG, 0.6 g/L) that persisted 10 years after Hodgkin occurrence.
Immunologic evaluation. Median serum immunoglobulin levels at diagnosis were similar in both the LOCID and CVID groups ( Table 2 ). The proportion of patients with normal IgM levels was comparable between both groups. The albumin level was 42 g/L in both groups. The results of lymphocyte subsets analysis and comparisons between patients with LOCID and patients with CVID are provided in Figure 1 and Tables 3 and  4 . As indicated, the total lymphocyte counts were lower among patients with LOCID, with a marked reduction in the T, B, and natural killer cell compartments. Within the T cell population, the reduction in absolute numbers was more marked for the CD4 + T cell population, as expected according to the definition of the LOCID group. The CD4 + T cell count was ! ). A re-P p .002 duction in the CD8 + T cell population was also observed among patients with LOCID ( vs cells/L; ), 6 6 221 ϫ 10 466 ϫ 10 P ! .001 which was associated with a reduction in the naive compartment (6% vs 19%;
). P ! .02 As indicated in Tables 3 and 4 , the total B cell count was notably reduced among patients with LOCID ( vs 6 20 ϫ 10 cells/L;
). Furthermore, 30% of patients with 6 103 ϫ 10 P ! .001 LOCID had a CD19 + B cell count р1% of the total lymphocyte count (BϪ group in the EuroClass classification) [8] + transitional B cells and CD21 low B cell percentages were similar among both groups.
DISCUSSION
CVID is a heterogeneous condition prone to highly variable clinical presentation and outcome. CVID is frequently associated with biological T cell disorders [9] . It is not known whether these T cell defects are primary or secondary because frequent lower respiratory tract infections may also induce T cell disorders [21] . We hypothesized that a severe T cell defect, as demonstrated by OI occurrence or low CD4 T lymphocyte count, is likely to be primary and part of the underlying immune defect. We have studied the relevance of clinical or biological severe T cell defect to define a possible distinct subset in CVID. The occurrence of OIs in CVID has only been reported as case reports [15] [16] [17] , pointed out in a few surveys [12, 13] , or not noted at all [22, 23] . Analyzing 313 patients with CVID from the French DEFI study, we found 17 patients (5.4%) who experienced OIs. These findings are similar to those reported in a large US survey [12] in which 13 (5.2%) of 248 patients with CVID experienced OIs. We defined a group of 28 patients with previous OIs or at higher risk for OIs (CD4 of the patients had thymoma. Immunosuppressive drug intake was reported equally in both groups. Direct genomic sequencing of the CD40L gene did not display any deleterious mutations in the male patients (data not shown) [24] . Plasma HIV RNA viral load was undetectable in all patients. We showed that these 28 patients with LOCID shared common demographic, clinical, and biological characteristics that set them apart from the remaining patients with CVID. A striking feature was the high frequency of consanguinity found in parents of patients with LOCID (29%), suggesting a possible recessive autosomic genetic disease. Patients with LOCID presented with a high prevalence of lymphoproliferative disorders. These complications have already been associated with abnormalities in T cell phenotype [9] (G. Mouillot, personal communication); it is therefore not surprising to find them associated with marked T cell immune deficiency. Although not documented in most of the cases from the present study, the high frequency of gastrointestinal disorders may be associated with cytomegalovirus or other pathogens [14, 25] . The overall clinical severity of the disease quantified on the basis of antibiotic use and hospitalization also appeared to be worse despite comparable immunoglobulin levels at diagnosis and immunoglobulin substitution requirements. Among patients receiving immunoglobulin substitution therapy, evolution toward chronic lung damage and bronchiectasis was more frequent among patients with LOCID (61% vs 37%; ). This finding may argue against an P p .021 exclusive role of the defective immunoglobulin production in determining the course of the bronchiectasis and for a possible role of T cell deficiency in the genesis of chronic infection and lung damage [26] [27] [28] .
Low lymphocyte counts could not be assigned to splenomegaly and hypersplenism because counts remained lower than those observed among patients with CVID with splenomegaly (data not shown). Despite the high frequency of gastrointestinal disorders, lymphocyte loss through the gut is unlikely because the albumin level remains in the reference range. Twenty-one of 28 patients with LOCID had a CD4 + T lymphocyte count ! cells/L and 16 had a count ! cells/L. A 6 6 400 ϫ 10 200 ϫ 10 higher proportion would have been expected in patients with HIV infection, the most frequent T cell immunodeficiency syn-drome. This strongly suggests an associated functional T cell disorder.
The low CD4 + T cell counts observed in LOCID patients were mainly associated with a significant decrease in naive CD4 + T cells and with a relative increase in activated, Fas (CD95)-exhibiting CD4 + T cells. Considering the late occurrence of OI, usually around the fourth decade of life, one may speculate on a possible progressive disappearance of the naive population. The design of the study with only 1 centralized phenotype record at evaluation prevents us from knowing the evolution of the CD4 + T cell count over time. However, immunophenotypes determined in local hospitals within 1 year or before study inclusion were available for 16 of the 17 patients with previous OIs. Among these patients, 8 had been studied at least once before the onset of OI. On those phenotypes, CD4 + T cell counts were in the same range as they were at evaluation. However, the stability of the phenotype needs confirmation by longitudinal studies with sequential immunophenotypes during a longer period.
Whether these patients with severe T cell defects should still be considered as having CVID remains an issue, and alternative diagnosis should be discussed. Idiopathic CD4 lymphocytopenia is a heterogeneous condition typically diagnosed in middle age, characterized by sustained CD4 + T cell counts ! cells/L [29] . Patients with idiopathic CD4 lympho-6 300 ϫ 10 cytopenia sometimes have slightly depressed IgG and/or IgA levels but usually do not experience recurrent infections suggestive of humoral immunodeficiency [30, 31] . Occasionally, CVID has been proposed as a differential diagnosis of CD4 + lymphocytopenia [32] . In the present series, the manifestations of cellular deficiency were preceded by years of symptomatic humoral deficiency and low serum IgG and IgA levels, which prompted us to consider them as CVID. Noteworthy is the substantial defect noted not only for the whole T cell population but also for natural killer cells and B cells. Subsequently, some of these patients could be considered as having combined immunodeficiency with a common early defect in lymphocyte differentiation rather than CVID. A few patients with a leaky form of adenosine deaminase deficiency have been reported. The clinical course was characterized by an adult onset of OIs and global lymphopenia [33, 34] . Even though the adenosine deaminase dosage in a previous cohort of patients with CVID did not reveal any deficiency [35] , it was not performed in our selected patients and we cannot therefore rule out such a hypothesis. Recently, LOCID was demonstrated in 3 children with hypomorphic RAG mutations [36] with maturation of a limited number of T and B cells. These children presented with extensive granulomatous disease; one had splenomegaly and another developed diffuse large B cell lymphoma. These children had rather atypical clinical features with mild infections compared with those observed in children with severe combined immunodeficiency, and this prompted the authors to extend the study to an additional cohort of 19 patients with CVID, but no functionally relevant RAG1 or RAG2 mutation was then demonstrated. However, RAG deficiency and other leaky defects for other severe combined immunodeficiencies, such as adenosine deaminase deficiency, should be considered in patients with evidence of combined humoral and cellular immunodeficiency. Under this hypothesis, the high prevalence of consanguinity in our series should be outlined.
In summary, CVID with severe T cell deficiency eventually differs from classic CVID through clinical presentation and immunologic phenotype and may therefore be considered as a distinct group of patients. Because these patients may have variants of severe combined immune deficiency, we suggest referring to them as having LOCID. The CD4 + T cell count appeared as a possible surrogate marker for clinical disease in most of these patients but not all. It is important that these findings be confirmed by prospective studies, including systematic recording of T cell phenotype in every patient with CVID. Discrimination of this phenotype should result in a more fitted diagnostic approach of infectious and lymphoproliferative complications and in possible specific prophylaxis. Furthermore, distinction of patients with LOCID could provide some interesting insights for further genetic research.
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